+40.2%
AMC vs GSK
+14.9%
+25.3%
-63.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +7.3% | +5.0% | +2.3% | +6.4% |
| 7D | +17.7% | +4.9% | +12.8% | +16.8% |
| 30D | +26.2% | +9.9% | +16.3% | +24.2% |
| 3M | +31.3% | +0.2% | +31.2% | +31.1% |
| 6M | +142.8% | +2.3% | +140.4% | +138.8% |
| YTD | +125.6% | +7.1% | +118.6% | +123.2% |
| 1Y | +40.2% | +13.1% | +27.1% | +31.9% |
| All | +40.2% | +14.9% | +25.3% | +31.9% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling